Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novocure Ltd Ord Sh (NQ: NVCR )

16.99 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 38
Open 16.99
Bid (Size) 16.60 (1)
Ask (Size) 17.29 (1)
Prev. Close 16.99
Today's Range 16.99 - 16.99
52wk Range 10.87 - 24.73
Shares Outstanding 103,647,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NovoCure (NVCR) Q3 2024 Earnings Call Transcript
NVCR earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Novocure Appoints Christoph Brackmann as Chief Financial Officer
From Novocure
Via Business Wire

Performance

YTD
+17.99%
+17.99%
1 Month
+8.70%
+8.70%
3 Month
-25.38%
-25.38%
6 Month
+33.57%
+33.57%
1 Year
+27.74%
+27.74%

More News

Read More
Novocure Reports Third Quarter 2024 Financial Results
From Novocure
Via Business Wire
Deep Dive Into NovoCure Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why NovoCure Stock Dived by 13% This Week
Via The Motley Fool
Beyond The Numbers: 4 Analysts Discuss NovoCure Stock
Via Benzinga
US Stocks Could Open Narrowly Mixed After Tuesday's Chip Sell-Off, Bitcoin Heads To $68K, Oil Slips
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
Via Benzinga
Exposures Product Safety
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
Via Investor's Business Daily
Exposures Product Safety
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Breaking Down NovoCure: 4 Analysts Share Their Views
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novocure to Report Third Quarter 2024 Financial Results
From Novocure
Via Business Wire
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
From Novocure
Via Business Wire
Novocure Announces Planned CEO Transition
From Novocure
Via Business Wire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Novocure to Participate in 2024 Wells Fargo Healthcare Conference
From Novocure
Via Business Wire
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
From Novocure
Via Business Wire
Chips, Glorious Chips!
Via The Motley Fool
PayPal Posts Upbeat Earnings, Joins Sprouts Farmers Market, Stanley Black & Decker, Phillips 66 And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Novocure Reports Second Quarter 2024 Financial Results
From Novocure
Via Business Wire
Novocure to Report Second Quarter 2024 Financial Results
From Novocure
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.